Yong 1

CURRICULUM VITAE, V. WEE YONG May 2004

A. IDENTIFICATION Name: Voon Wee Yong Current Position: Professor, University of Calgary Office Address: Departments of Oncology and Clinical Neurosciences

University of Calgary 3330 Hospital Drive NW Calgary, Alberta T2N 4N1

Telephone: 403-220-3544 Fax: 403-283-8731 E-mail: vyong@ucalgary.ca Date of Birth: January 28, 1957 Spouse: Fiona P. Yong Children: Sasha, Emma and Heather B. EDUCATION Undergraduate: University of Manchester, Manchester, England

Pharmacology, B.Sc. (Hons), 1978 - 1981 Graduate: University of British Columbia, Vancouver, Canada

Pharmacology and Neurochemistry, Ph.D., 1981 - 1986 Supervisor: Dr. Thomas L. Perry Sr.

Post-graduate: University of British Columbia, Canada, on Glial Cell Biology, 1986 - 1988.

Supervisor: Dr. Seung U. Kim C. APPOINTMENTS 1986 – 1988: Lecturer, Department of Pharmacology and Therapeutics,

University of British Columbia 1989 – 1994: Assistant Professor, Department of Neurology and Neurosurgery,

McGill University 1994 – 1996: Associate Professor, Department of Neurology and Neurosurgery,

McGill University, with tenure

Yong 2 1996 – 2001: Associate Professor, Departments of Oncology and Clinical Neurosciences,

University of Calgary 2001 – present: Professor, Departments of Oncology and Clinical Neurosciences, University of

Calgary D. SPECIAL DISTINCTIONS

Scholar. Medical Research Council of Canada, 1989 – 1994 Scholar. Fonds de la Recherche en Santé du Québec, 1989 – 1994

Senior Scholar, Alberta Heritage Foundation for Medical Research, 1998 - present

Scientist, Canadian Institutes for Health Research, 1998 – present Cochrane Distinguished Achievement Award for excellence in research, Faculty of Medicine, University of Calgary, 2000 Multiple Sclerosis Society of Canada 2000 National Certificate of Merit, Member Award. This award is given to one individual for “outstanding contribution by a member of the Mutliple Sclerosis Society of Canada in furthering its work on a national basis”.

Awardee, Queen Elizabeth II’s Golden Jubilee Year Medallion, Canada, for Multiple Sclerosis activities, 2002 Canada Research Chair (Tier I) in Neuroimmunology, 2004 - present

E. CURRENT ACTIVE RESEARCH OPERATING GRANTS

1. Canadian Institutes for Health Research, Regulation and functions of neuroinflammation in spinal cord injury, 2004 - 2009, $157,165 per annum

2. Multiple Sclerosis Society of Canada, Beneficial roles of matrix metalloproteinases (MMPs)

in myelin formation, 2004- 2007, $117,250 per annum

3. Canadian Institutes for Health Research, Battle for the brain: Glioma versus glia, 2003-2007, $146,000 per annum

4. Canadian Institutes for Health Research, Interdisciplinary Health Research Team

Program, Matrix metalloproteinases in multiple sclerosis: Environmental influence, biology, pathology and therapeutic strategies. I am the director, and there are 14 other co-applicants (Jack Antel, Amit Bar-Or, Pierre Duquette, Dylan Edwards, Peter Forsyth, Charlie Hao, Paul Kubes, Luanne Metz, Ross Mitchell, Trevor Owens, Scott Patten, Jim Peeling, Christopher

Yong 3

Power and Steven Robbins). The award is a total of $989,650 per annum for the whole team, from 2001 – 2006. $119,863 is awarded for equipment in 2001.

5. Serono Canada, Analyses of the combination of interferon-β and Minocycline in EAE: Future

Prospects for treatment in MS, 2003-2004, $55,000

6. IVIG Steering Committee/Bayer, Neuroprotection by IVIG, 2003-2004, $91,000

F. BRIEF DESCRIPTION OF MY RESEARCH INTERESTS Neuroimmunology is the study of inflammation in the nervous system. Virtually all neurological disorders have inflammatory components, and these include diseases traditionally associated with overt inflammation, such as multiple sclerosis (MS), and those previously thought to be purely degenerative, including Alzheimer’s disease. Neuroinflammation originates from the trafficking of several leukocyte subsets into the nervous system and through the production of immune molecules by neural cells themselves. The interaction between leukocytes and neural cells further promotes neuroinflammation and injury. In recent years, reparative properties of neuroinflammation have been appreciated, so that the balance between beneficial and detrimental neuroinflammation is a crucial determinant of outcome. My research projects have been guided by 3 diseases of the central nervous system (CNS): MS, spinal cord injury (SCI) and brain tumors (malignant gliomas). MS and SCI provide my research program with diseases of chronic and acute neuroinflammation, respectively. In contrast, malignant gliomas present a disease of immunosuppression, whereby the cancer cells neutralize the activity of leukocytes that infiltrate into these tumors. Collectively, my studies of these 3 diseases are aimed at understanding, controlling and tipping the balance of neuroinflammation towards one of neuroprotection and regeneration from CNS insults. G. NATIONAL OR INTERNATIONAL CONFERENCE INVITATIONS: 1. Workshop speaker, Workshop on Role of Astrocytes in Inflammatory Demyelination, organized

by the U.S. Multiple Sclerosis Society, at Galveston, Texas. My presentation topic was: g-interferon from CD4 and CD8 lymphocytes is a proliferative agent for human adult astrocytes. Date: 1990

2. Invited Workshop discussant at the Boehringer Ingelheim Fonds International Titisee

Conferences, Titisee, Germany, on Neuroimmune networks: Cell-cell communication and response to injury and regeneration in the CNS. Date: 1992

3. Invited Workshop Speaker, Gordon Conference on Myelin, New Hamsphire. My presentation

topic was: Cytokines as mediators of Gliosis. Date: 1992 4. Invited Symposium speaker, 6th Canadian Neuro-Oncology Meeting, Lake Louise, Alberta.

Presntation topic: Growth factors and signal transduction in malignant gliomas. Date: May 1994

Yong 4 5. Invited Workshop speaker, Workshop on macrophages, microglia and immunity, XIIth

International Congress of Neuropathology, Toronto. Presentation topic: Human microglia in culture. Date: September 1994

6. Invited Symposium speaker, 4th Chicago Institute of Neurosurgery and NeuroResearch

Symposium, Chicago. Presentation topic: Abnormalities of protein kinase C signal transduction in malignant gliomas. Date: October 1994

7. Invited symposium speaker, International symposium on Pathophysiology of astrocytes and

microglia: focus on multiple sclerosis and HIV-related brain damage, Rome, Nov 1995. My presentation topic was: Inflammatory cytokines as regulators of reactive astrogliosis

8. Invited symposium speaker, 4th International Altschul Symposium on Cell biology and pathology

of myelin: Evolving biological concepts and therapeutic approaches, Saskatoon, June 1996. My presentation topic was: Protein kinase C and process formation in oligodendrocytes.

9. Workshop co-organizer and speaker, in workshop on protein kinase C in glia, at the Joint Meeting

of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, July 1997. My presentation topic was: PKC in oligodendrocytes: Regulation of process formation and matrix metalloproteinase-9 activity.

10. Invited symposium speaker, 7th Chicago Institute of Neurosurgery and NeuroResearch

Symposium, Chicago, November 1997. My presentation topic was: Protein kinase C and matrix metalloproteinases as regulators of glioma growth and invasiveness.

11. Invited Workshop Speaker, Gordon Research Conference on Myelin, Ventura, Feb 1-6, 1998.

My presentation topic was: Inflammatory cytokines and reactive astrogliosis: Relevance to oligodendrocyte biology.

12. Invited symposium chairperson. Title of symposium: CNS as an immune organ. At the 5th

International Congress of Neuroimmunology, Montreal, August 23 - 27, 1998 13. Chairman and co-organiser, International Conference on Metalloproteinases and their Inhibitors

in the Nervous System: Physiology and Disease, Banff, Feb 27 - March 3, 1999. My presentation topic: MMPs in oligodendrocyte biology and myelin formation.

14. Invited speaker, 5th Altschul Symposium on The role of Inflammation in mediating damage

following stroke and neurotrauma, Saskatoon, August 18 – 21, 1999. My presentation topic: Mediators and functions of neuroinflammation following CNS trauma.

15. Invited speaker, Immunology Conference on Pathogenesis and Immunotherapy in Autoimmunity,

Sept 30 – Oct 3, 1999, Emerald Lake, Alberta. My presentation topic: T cell – microglia interactions.

16. Invited faculty, Contemporary approaches to the management of multiple sclerosis, Teva Marion

Partners, Whistler, Nov 12 – 14, 1999. My presentation topic: Immunology for the neurologists. 17. Invited faculty, Focus group on multiple sclerosis treatment, Toronto, Dec 15, 1999. My

presentation topic: Immunology for the neurologists.

Yong 5 18. Invited speaker, Canadian Digestive Week 2000. Symposium on Neuroinflammation: Nitric

Oxide and GI pathology. My presentation topic: Mediators and functions of neuroinflammation in CNS trauma, March 10, 2000, Quebec City

19. Invited speaker, American Society for Neurochemistry, Symposium on Injury-associated

cytokines as mediators of reactive gliosis and CNS recovery, March 26 – 29, 2000, Chicago. 20. Invited speaker, FASEB summer conference on Neural-Immune interactions in injury and

disease: pathways to therapy, Colorado, June 18 – 23, 2000. My presentation topic: Matrix metalloproteinases and oligodendrocyte development.

21. Invited speaker, Brain Tumor Symposium, Scientific Meeting of Singapore – Malaysia Medical

Societies, August 4, 2000, Singapore. My presentation title: Regulation of glioma motility and invasiveness.

22. Selected speaker, ACTRIMS (Americas Committee for treatment and research in multiple

sclerosis), October 15, 2000, Boston. My presentation title: Targeting matrix metalloporteinases in MS: minocycline as a novel therapeutic strategy.

23. Jerry Olszewski Lecturer, Annual Meeting of the Canadian Association of Neuropathogists,

October 19 – 21, 2000, Banff. My presentation title: Complexities of neuro-inflammation: Pathology and regeneration.

24. Convenor and speaker, Symposium on MMPs, International Society for Neuroimmunology

Congress, Edinburgh, Sept 4-7, 2001. My presentation title:: MMPs in CNS Repair and Regeneration.

25. Invited Speaker, British Society for Matrix Biology, Sept 3, 2001, Norwich, on: MMPs in the

CNS – Friend or foe? 26. Faculty, Update on Multiple Sclerosis Course (Coordinator: A Miller), American Academy of

Neurology, Denver, April 14, 2002. My presentation: Mechanisms of immunomodulators used in MS.

27. Faculty, 5th International Workshop on Maturation Phenomenon in Cerebral Ischemia, April 28 -

May 1, 2002. My presentation: Modulation of CNS pathology and recovery by matrix metalloproteinases (MMPs).

28. Faculty, Symposium on Milestones in the first decade of intervention: Effective treatment

strategies in MS, during the Consortium of MS Clinics meeting, Chicago, June 6, 2002. My presentation topic: Attenuating neuroinflammation and achieving neuroprotection in MS: How have we done with interferon-β and glatiramer actetate?

29. Speaker, American and European Committees for Treatment and Research in Multiple Sclerosis

(ACTRIMS/ECTRIMS), Sept 19 –22, 2002, on: Matrix metalloproteases

Yong 6 30. Faculty, Update on Multiple Sclerosis Course (Coordinator: A Miller), American Academy of

Neurology, Honolulu, March 30, 2003. My presentation: MS Pathology and therapeutics: New scientific insights

31. Faculty, American College of Osteopathic Neurologists and Psychiatrists, April 10-12, 2003,

Scottsdale, Arizona. My presentation topic: New insights in MS. 32. Coordinator and Speaker, Symposium on MMPs in the nervous system, at the 34th Annual

Meeting of the Society for Neurochemistry, NewPort, CA, May 3-8, 2003. My presentation topic: Complexities of MMPs in the CNS.

33. Speaker, NIH Workshop on Glial Inflammation in HIV-1 and Chronic Degenerative Diseases,

Washington, December 7 – 10, 2003. My presentation topic: MMPs – Detrimental and Beneficial Aspects.

34. Invited participant, 1st International Campaign for cures of spinal cord injury paralysis (ICCP)

workshop, Vancouver, Feb 20-21, 2004 35. Invited participant, NIH Workshop on Biomarkers in MS, Washington, April 14 – 16, 2004 36. Faculty, Second Course on Molecular mechanisms of Brain Tumors, Sponsored by the American

Brain Tumor Association, May 12-16, 2004. My presentation topic: Chemokines and matrix metalloproteinases in malignant gliomas.

37. Speaker, Symposium on Degradation and repair of myelin: Role of proteases and complement,

American Society for Neurochemistry meeting, New York, August 13-19, 2004 38. Speaker, Keystone Symposium on: Central nervous system inflammation: mechanisms,

consequences and therapeutic strategies, Jan 11-15, 2005, Snowbird, Utah. My presentation topic: Matrix metalloproteinases

Other talks/seminars given (listing given only for 2000 - 2004) 1. Seminar, Centre de Recherche, CHUL, University of Laval, March 10, 2000, on: Matrix

metalloproteinases in the CNS: Disease and Recovery. 2. Morning Rounds Speaker, MS Clinic of St. Michael’s Hospital, University of Toronto, March 30,

2000, on: Mechanisms of Drugs used in MS treatment 3. Grand Rounds Speaker, Trillum Medical Centre, Mississauga, March 31, 2000, on: Mechanisms

of Drugs used in MS treatment 4. Speaker, Dinner Program to Neurologists, on behalf of Teva Marion Partners, Canada, March 29

(Toronto), and March 30 (Hamilton), 2000

Yong 7 5. Lecturer, Teva Marion Partners Sales School, Kansas City, April 11, 2000, on: Basic

Immunology with the Expert 6. Seminar, Montreal General Hospital Neuroscience Soree, May 31, 2000, on: Matrix

metalloproteinases in the CNS: Disease and Recovery 7. Lecturer, Teva Marion Partners Sales School, Kansas City, June 6, 2000, on: Basic Immunology

with the Expert 8. Speaker, Rocky Mountain MS Center, Denver, June 21, 2000, on: Mechanisms of drugs used in

MS therapy 9. Grand Rounds speaker, University Hospital, University of Malaya, July 19, 2000, on: Glial cells

in health and disease 10. Seminar Speaker, Department of Anatomy, University of Singapore, August 4, 2000, on:

Complexities of neuro-inflammation: Pathology and regeneration 11. Lecturer, Current Advances in Immunomodulatory Therapy, August 25 – 27, 2000, Banff. My

title: Immunology of multiple sclerosis: How do multiple sclerosis therapies work? 12. Speaker, Dinner Program to Neurologists, on behalf of Teva Marion Partners, Chicago,

November 10, 2000 13. Grand Rounds speaker, Department of Oncology, University of Calgary, Dec 20, 2000, on: To Go

or Grow: The Song and Dance of Glioma cells. 14. Lecturer, Mechanisms of action of interferon-β and copaxone in MS, Kansas City, February 5,

2001 15. Seminar Speaker, University of Louisville, Kentucky, February 8, 2001, on: Complexities of

neuro-inflammation: Pathology and regeneration 16. Neuroscience Seminar Speaker, University of Alberta, March 8, 2001, on: Complexities of neuro-

inflammation in CNS recover: Friend or foe? 17. Clinical Neuroscience Grand Rounds Speaker, University of Alberta, March 9, 2001, on:

Immunomodulators in multiple sclerosis: Mechanisms of action and prospects for enhancing their efficacy

18. Dinner Speaker, Sponsored by the New York Chapter of the National Multiple Sclerosis Society,

April 16, 2001, on Interferon-β and glatiramer acetate in MS: Comparisons and contrasts 19. Seminar Speaker, Neuropathology Seminar Series, Albert Einstein College of Medicine, New

York, April 17, 2001, on: Matrix metalloproteinases (MMPs) in the CNS: Friend and Foe 20. Grand Rounds Speaker, Department of Clinical Neurosciences, University of Calgary, April 20,

2001, on: The battle for the brain: Glioma versus glia

Yong 8 21. Faculty, TEVA Neuroscience Northeast, Great Lakes and Mid-East Regional Advisory Meeting,

April 27-29, 2001, Key Largo, Florida, on Interferon-β and glatiramer acetate in MS: Comparisons and contrasts

22. Speaker, Serono Institute, Geneva, May 22, 2001, on: Matrix metalloproteinases as targets for

therapeutics in neuro-inflammatory diseases 23. Speaker, BC MS Educational Symposium, Vancouver, July 13, 2001, on: Mechanisms of drugs at

the blood-brain barrier 24. Faculty, TEVA Neuroscience Mid-East Regional Advisory Meeting, July 21, 2001, Baltimore, on

Interferon-β and glatiramer acetate in MS: Comparisons and contrasts 25. Faculty, TEVA Neuroscience Northeast Regional Advisory Meeting, August 10-12, 2001,

Newport, Rhode Island, on: Detrimental and beneficial aspects of CNS inflammation: Glatiramer acetate and protective autoimmunity

26. Faculty, TEVA Neuroscience South-East Regional Advisory Meeting, August 17-19, 2001,

Amelia Island, Florida, Glatiramer acetate and the interferons: Differentiating the mechanistic actions

27. Speaker, Grand Rounds, Department of Neurology, University of Michigan, October 17, 2001,

on: Immunomodulators in multiple sclerosis: Mechanisms of action and prospects for enhancing their efficacy.

28. Dinner speaker, Detroit, October 17, 2001, on: Mechanisms of drugs used in MS. 29. Faculty, TEVA Neuroscience Northeast Regional Advisory Meeting, October 26-28, 2001,

Bermuda, on: Complexities of CNS inflammation: Glatiramer acetate and neuroprotection. 30. Dinner speaker, Toronto, October 30, 2001, on: Mechanisms of drugs used in MS. 31. Speaker, University of South Florida College of Medicine, November 7, 2001, on:

Immunomodulating therapies: Mechanisms of action and basis for differential clinical presentations.

32. Seminar Speaker, Mucosal Inflammation Group, University of Calgary, November 21, 2001, on:

Functions of CNS Inflammation: Sorting through the Mess 33. Lecturer, Serono USA, Boston, on: Immunology and the mechanisms of interferon-β in MS,

January 10, 2002 34. Grand Rounds Speaker, Department of Neurology, Virginia Commonwealth University, Feb 14,

2002, on:Targeting neuroinflammation and matrix metalloproteinases in multiple sclerosis 35. Seminar speaker, Department of Anatomy and Molecular Biology, Virginia Commonwealth

University, Feb 15, 2002, on: Dual roles of matrix metalloproteinases in CNS pathology and recovery

Yong 9 36. Faculty, TEVA Neuroscience Northwest Regional Advisory Meeting, Seattle, Feb 22-23, 2002,

on: Tergeting neuroinflammation: Mechanisms of copaxone and interferon-β in MS 37. Seminar Speaker, MS Interest Group, University of Calgary, March 6, 2002, on: Pathology of MS

and therapeutic considerations 38. Faculty, TEVA Neuroscience South Central and Southeast Regional Advisory Meeting,

Snowbird, Utah, March 7 - 10, 2002, on: A) Immunologic mechanisms of GA and interferon-β in MS; and B) MR findings: Is there a case for neuroprotection?

39. Grand Rounds Speaker, Christiana Hospital, Philadelphia, March 21, 2002, on: Targeting

neuroinflammation in MS 40. Grand Rounds Speaker, Cooper Hospital, Philadelphia, March 22, 2002, on: Targeting

neuroinflammation in MS 41. Seminar Speaker, University of Mannitoba, April 3, 2002, on: Matrix metalloproteinases in the

CNS: Friend and foe 42. Faculty, The Canadian Network of MS clinics, Multiple Sclerosis Preceptorship, May 2-5, 2002,

Vancouver. Presentation topic: Immunologic insight into MS 43. Dinner speaker, May 13, 2002, Dayton, Ohio, and May 14, Columbus, Ohio, on: Targeting

neuroinflammation: Mechanisms of copaxone and interferon-β in MS 44. Neurology Grand Rounds, St. Michael’s Hospital, University of Toronto, May 16, 2002, on:

Neuroinflammation and neuroprotection: New concepts and therapeutics in MS 45. Dinner speaker, Madison, June 7, 2002, on: Immunopathogenesis of MS and mechanisms of

action of interferon-β and copaxone 46. Seminar speaker, June 14, 2002, University of California at San Francisco, on:

Neuroinflammation and neuroprotection: New concepts and therapeutics in MS 47. Faculty, June 14, 2002, San Francisco, Teva Neuroscience program, on: Targeting

neuroinflammation and neuroprotection: Mechanisms of copaxone and interferon-β in MS 48. Faculty, Program for Toronto neurologists, June 27, 2002, on: Targeting neuroinflammation and

neuroprotection: Mechanisms of copaxone and interferon-β in MS 49. Seminar speaker, July 31, 2002, University of Singapore, on: Battle for the brain: Glia versus

Glioma 50. Faculty, TEVA Neuroscience South West, North West and North Central Regional Advisory

Meeting, Anchorage, Alaska, August 22-25, 2002, on: Achieving neuroprotection in MS 51. Dinner speaker to neurologists, New York City, August 28, 2002, on: Neuroprotection for MS:

Where are we in 2002?

Yong 10 52. Seminar speaker, Harvard University (Beth Israel Hospital), August 29, 2002, on:

Neuroinflammation and neuroprotection: New concepts and therapeutics in MS 53. Speaker, Satellite symposium at ACTRIMS/ECTRIMS, Sept 20, 2002, Baltimore, on: Milestones

in immunomodulatory therapy: Decision in the treatment of multiple sclerosis 54. Speaker, First annual meeting of the Institute for Neuroscience, Mental Health and Addiction of

the Canadian Institutes of Health Research, Montreal, Oct 5-6, 2002, on: MMPs in MS 55. Neurology Grand Rounds, Henry Ford Hospital, Detroit, Oct 10, 2002, on: Neuroinflammation

and neuroprotection: New concepts and therapeutics in MS 56. Faculty, Oregon Health and Science University Multiple Sclerosis Retreat for trainees and

mentors, Sunriver, Oregon, Oct 17-20, 2002, on: A) Overview of Immunology of MS and MOA of disease modifying therapies, and B) Neurodegeneration and neuroprotection in MS

57. Neurology Grand Rounds, University of Missouri, Kansas City, Oct 25, 2002, on: New concepts

and therapeutics in MS 58. Faculty, Multiple Sclerosis/Parkinson’s Update Program, University of South Florida College of

Medicine, Charleston, Nov 2-3 , on: Immunomodulatory therapies: Mechanisms of action and basis for different clinical presentations

59. Grand Rounds Speaker, Thomas Jefferson University, Philadelphia, Nov 13, 2002, on:

Neuroinflammation and neuroprotection: New concepts and therapeutics in MS 60. Seminar Speaker, University of Pennsylvania, Philadelphia, Nov 14, 2002, on Matrix

metalloproteinases in multiple sclerosis and CNS regeneration 61. Faculty, Clinical Neurology Update, San Antonio, Nov 21-23, 2002, on: Immunopathogenesis of

MS and mechanisms of action of interferon beta and copaxone 62. Faculty speaker, Banff Inflammation Workshop, Banff, Jan 21 – Feb 2, 2003, on: Complex roles

of matrix metalloproteinases in the CNS 63. Faculty, TEVA Neuroscience Northeast Regional Advisory Meeting, Beaver Creek, Colorado,

Feb 6 – 9, 2003, on: Pathogenesis of MS: From inflammation to neuroprotection and regeneration 64. Faculty, TEVA Neuroscience Northwest, Southwest USA and Western Canada Regional

Advisory Meeting, Squaw Creek, California, Feb 27 – March 2, 2003, on: Immunopathogenesis of MS and the basis for therapy: GA effect on T cells, and on: Complexities of CNS inflammation: GA and neuroprotection

65. Faculty, TEVA Neuroscience Southeast, South Central and Midwest Regional Advisory Meeting,

Squaw Creek, California, March 20-23, 2003, on: Complexities of CNS inflammation: GA and Neuroprotection

66. Seminar, Memorial University, Newfoundland, April 22, 2003, on: Matrix metalloproteinases in

the CNS: Friend and foe

Yong 11 67. Neurology Grand Rounds, University of Saskatchewan, Saskatoon, May 16, 2002, on: Progress in

MS Research 68. Dinner speaker to neurologists, St. John’s, Newfoundland, Pathology of MS and prospects for

Neuroprotection in the disease, May 21, 2003 69. Dinner speaker to neurologists, St. John, New Brunswick, Pathology of MS and prospects for

Neuroprotection in the disease, May 22, 2003 70. Workshop for senior neurology residents, Canadian Congress of Neurological Sciences, Quebec,

June 16, 2003, on: Neuroimmunology in CNS degeneration and regeneration 71. University of South Florida College of Medicine’s CMS program to neurologists, Novi,

Michigan, June 26, 2003, on: Pathology of MS and prospects for Neuroprotection in the disease 72. Faculty, TEVA Neuroscience Great Lakes Regional Advisory Meeting, Pittsburgh, June 28, on:

Contrasting MOA of interferon-β and glatiramer acetate 73. Faculty, TEVA Neuroscience Northwest and North Atlantic Regional Advisory Meeting,

Anchorage Alaska, July 17-20, 2003 on: Beneficial Inflammation, Neuroprotection and Remyelination in MS: The Role of Glatiramer Acetate.

74. Neurology Grand Rounds, University of Southern California, August 12, 2003, on: Complexities

of CNS Inflammation and the Potential for Neuroprotection in MS. 75. Neurology Grand Rounds, University of California, Irvine, August 13, 2003, on: Complexities of

CNS Inflammation and the Potential for Neuroprotection in MS. 76. Dinner Speaker to neurologists, Orange County Neurological Society August 12, 2003, on:

Pathology of MS and Prospects for Neuroprotection in the Disease. 77. Faculty, Symposium on Neuroimmunology of multiple sclerosis, University of Utah, September

12, 2003, on: Immunology of multiple sclerosis and approaches to immunotherapy 78. Speaker, CME Program, Strongsville, Ohio, September 22, 2003, on: Pathology of MS and

prospects for Neuroprotection in the disease. 79. Seminar Speaker, Toronto Western Hospital, University of Toronto, October 7, 2003, on:

Complex but key roles of matrix metalloproteinases in CNS pathology and recovery 80. Speaker, Grand Rounds, University Hospitals of Cleveland, Case Western Reserve University,

November 7, 2003, on: Neuroinflammation and Neuroprotection: New concepts and therapeutics in MS

81. Speaker, CME Program, Miami, Florida, November 25, 2003, on: MS therapeutics: Mode of

action predicts clinical outcome

Yong 12 82. Speaker, Neurology Program, Washington, on: Immunology of MS therapeutics and

Neuroprotection, December 8, 2003 83. Grand Rounds, Oregon Health Sciences University, Portland, Oregon, Feb 4, 2004, on:

Neuroinflammation and neuroprotection: new concepts and therapeutics in MS 84. Speaker, Grand Rounds, University of Iowa, February 10, 2004, on: Neuroinflammation and

neuroprotection: new concepts and therapeutics in MS. 85. Speaker, Grand Rounds, University of New Mexico, Albuquerque, February 27, 2004, on:

Neuroinflammation and neuroprotection: new concepts and therapeutics in MS. 86. Special consultant, Serono Meeting on MMP inhibitors in neurological diseases, Geneva, March

2, 2004 87. Faculty, Teva Neuroscience Multiple Sclerosis Regional Advisory Meeting, March 19 – 21, 2004,

Las Vegas. Presentation on: Inflammation, neurodegeneration and Neuroprotection: mechanistic considerations for therapy selection

88. Speaker, Neurology Grand Rounds, Trillum Hospital, Mississauga, April 30, 2004, on: Progress

in MS research and therapy 89. Speaker, Neurology Grand Rounds, University of Texas, Houston, May 14, 2004, on: An update

on MS pathogenesis and therapies Not included here are pre-2000 invitations to speak at other universities that include the University of Maryland, Cleveland Clinic Foundation, Laval University, National University of Singapore, Dalhousie University, University of Ottawa, University of Saskatoon, University of British Columbia, McGill University, and Scripps Research Instutute, La Jolla.

H. LIST OF PUBLICATIONS

Refereed papers in the past 5 years (italicized references are from this laboratory)

81. Chabot S, Williams G, Hamilton M, Sutherland G, Yong VW, Mechanisms of IL-10 production

generated from the interaction between T cells and microglia, J Immunol 162:6819-6828, 1999 82. Price A, Shi Q, Morris D, Wilcox ME, Brasher PMA, Rewcastle NB, Shalinsky D, Appelt K,

Johnston RN, Yong VW, Edwards D, Forsyth P, Marked inhibition of tumor growth in a

Yong 13

malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340, Clin Cancer Res 5:845-854, 1999

83. Ng YK, Yong VW, Ling EA, Microglia reaction in CNS nuclei following nerves transection in

BALB/c and interferon-γ gene knockout mice, Neurosci Lett 262:207-210, 1999 84. Yong VW, The potential use of MMP inhibitors to treat CNS diseases, in: Expert Opinion on

Investigational Drugs 8:255-268, 1999 85. Besson A, Robbins SM, Yong VW, PTEN/MMAC1/TEP1 in signal transduction and

tumorigenesis, Eur J Biochem 263:605-611, 1999 86. Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, Antel JP, Yong VW, Migratory behavior

of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy, Ann Neurol 46:319-324, 1999

87. Oh LYS, Krekoski C, Donovan F, Edwards D, Werb Z, Yong VW, Gelatinase B/Matrix

metalloproteinase-9 is required for oligodendroglial process extension in vivo and in vitro, J Neurosci 19:8464-8475, 1999

88. Besson A, Yong VW, Involvement of p21Waf1/Cip1 in protein kinase C alpha-induced cell cycle

progression, Mol Cell Biol 20:4580-4590, 2000 89. Vecil GG, Larsen PH, Herx LM, Besson A, Goodyer CG, Yong VW, Interleukin-1 is a key

regulator of matrix metalloproteinase-9 in human neurons in culture and following mouse brain trauma in vivo, J Neurosci Res 61:212-224, 2000

90. Herx LM, Rivest S, Yong VW, Central nervous system-initiated inflammation and neurotrophism

in trauma: IL-1β is required for the production of ciliary neurotrophic factor, J Immunol 165:2232-2239, 2000

91. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian

E, Cerullo L, Leestma J, Moskal JR, The identification of novel therapeutic targets for the treatment of malignant brain tumors, Cancer Lett 156:191-198, 2000

92. Chabot S, Yong VW, Interferon-β1b increases IL-10 in a model of T cell - microglia interaction:

relevance to MS, Neurol 55:1497-1505, 2000 93. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni L, Holden JK, Corbett D, Yong

VW, Power C, HIV-1 tat neurotoxicity prevented by matrix metalloproteinase inhibitors, Ann Neurol 49:230-241, 2001

94. Hao CH, Chen HT, Van Meir EG, Yong VW, Beguinot F, Parney IF, Rao WH, Petruk KC,

Induction and intracellular regulation of TRAIL-induced apoptosis in human malignant glioma cells, Cancer Res 61:1162-1170, 2001

95. Chabot S, Charlet D, Wilson TL, Yong VW, Cytokine production in T cell – microglia

interaction: The PMA/IFNγ-treated U937 monocytoid cells as a model of human adult microglia, J Neurosci Methods 105:111-120, 2001

Yong 14 96. McDonald JR, McManaman JL, Yong VW, The therapeutic potential of chemokine-toxin fusion

proteins, Idrugs 4:427-442, 2001 97. Yong VW, Power C, Forsyth P, Edwards DR, Metalloproteinases in biology and pathology of the

nervous system,Nature Reviews Neuroscience 2:502-511, 2001 98. Besson A, Yong VW, Mitogenic signaling and the relationship to cell cycle regulation in

astrocytomas, in special issue of J Neurooncol 51:245-264, 2001 99. Couldwell WT, Yong VW, Glioma invasion, J Neurosurg 95:379-380, 2001 100. Panenka W, Jijon H, Herx LM, Armstrong JA, Feighan D, Wei T, Yong VW, Ransohoff RM,

MacVicar BA, P2X7-Like Receptor Activation in Astrocytes Increases Chemokine Monocyte Chemoattractant Protein-1 Expression via Mitogen-Activated Protein Kinase, J Neurosci. 21 7135-7142, 2001

101. Herx LM, Yong VW, Interleukin-1β is required for the early evolution of reactive astrogliosis

following CNS trauma, J Neuropathol Exp Neurol 60:961-971, 2001 102. Corley SM, Ladiwala U, Besson A, Yong VW, Astrocytes attenuate oligodendrocyte death in

vitro through an α6 integrin – laminin dependent mechanism, GLIA 36:281-294, 2001 103. Besson A, Davy A, Robbins SM, Yong VW, Differential activation of ERKs to focal adhesions by

PKCε is required for PMA-induced adhesion and migration of human glioma cells, Oncogene,20:398-407, 2001

104. Brundula V, Rewcastle B, Metz L, Bernard CC, Yong VW, Targeting leukocyte MMPs and

transmigration: Minocycline as a novel therapeutic for multiple sclerosis, Brain 125:1297-1308, 2002

105. Besson A, Yong VW, The anchoring protein RACK1 links protein kinase Cε to integrin β chains:

requirement for adhesion and motility, J Biol Chem 277:22073-22084, 2002 106. Chabot S, Le DM, Yong FP, Metz LM, Myles T, Yong VW, Cytokine production in T

lymphocyte-microglia interaction is attenuated by glatiramer acetate: A mechanism for therapeutic efficacy in multiple sclerosis, Multiple Sclerosis 8:229-306, 2002

107. Saulnier R, De Repentigny Y, Yong VW, Kothary R, Alterations in myelination in the central

nervous system of dystonia musculorum mice, J Neurosci Res 69:233-242, 2002 108. Yong VW, Differential mechanisms of action of interferon-β and glatiramer acetate in MS,

Neurology 59:802-808, 2002 109. Webber CA, Hockings JC, Yong VW, Stange C, McFarlane S, Metalloproteases and guidance of

retinal axons in the developing visual system, J Neuroscience 22:8091-8100, 2002 110. Zhou Y, Larsen PH, Hao CH, Yong VW, CXCR4 is a major chemokine receptor on glioma cells

and mediates their survival, J Biol Chem 277:49481-49487, 2002

Yong 15

111. Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, Edwards, Elevated Membrane-Type Matrix Metalloproteinases in Gliomas Revealed by Profiling Proteases and Inhibitors in Human Cancer Cells, Mol Cancer Res 1:333-345, 2003

112. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW, Nuttall RK, Pennington

CJ, Edwards DR, Bar-Or A, Determinants of Human B cell migration across brain endothelial cells, J Immunol 170:4497-4505, 2003

113. Takahashi JT, Imai Y, Power C, Yong VW, Interleukin-1β promotes oligodendrocyte death through glutamate excitotoxicity, Ann Neurol 53:588-595, 2003

114. Le DM, Besson A, Fogg D, Choi, Goodyer C, Rewcastle B, Waisman D, Yong VW, Exploitation

of astrocytes by glioma cells to facilitate invasiveness: A mechanism involving MMP-2 and the uPA - plasmin cascade, J Neuroscience 23:4034-4043, 2003

115. Power C, Henry S, del Bigio MR, Larsen PH, Corbett D, Imai Y, Yong VW, Peeling J, Induction

of matrix metalloproteinases following intracerebral hemorrhage: minocycline mediates MMP-12 inhibition and neuroprotection, Ann Neurol 53:731-742, 2003

116. Wells J, Hurlbert J, Fehlings M, Yong VW, Neuroprotection by Minocycline Facilitates

Significant Recovery from Spinal Cord Injury, Brain 126:1628-1637, 2003 117. Giuliani F, Goodyer CG, Yong VW, Selective and remarkable vulnerability of human neurons

to T cell-mediated cytotoxicity, J Immunol 171:368-379, 2003 118. Wells JE, Rice T, Nuttal RK, Edwards DR, Zekki H, Rivest S, Yong VW, An adverse role for

matrix metalloproteinase (MMP)-12 following spinal cord injury in mice, J Neurosci 23:10107-10115, 2003

119. Bar-Or A, Nuttall R, Duddy M, Alter A, Pennington C, Bourgoin P, Edwards D, Yong VW,

Analyses of all MMP members in leukocytes emphasize monocytes as major inflammatory mediators in MS, Brain 126:2738-2749, 2003

120. Larsen PH, Wells J, Stallcup WB, Opdenakker G, Yong VW, Matrix metalloproteinase-9 (MMP-

9) facilitates remyelination by processing the inhibitory NG2 proteoglycan, J Neurosci 23:11127-11135, 2003

121. Giuliani F, Yong VW, Immune-mediated neurodegeneration and neuroprotection in Multiple

Sclerosis, The International MS Journal 10:122-130, 2003 122. Zhang W, Nwagwu C, Le DM, Yong VW, Song H, Nedergaard M, Couldwell WT, Increased

invasive properties in connexin 43-overexpressing malignant glioma cells, J Neurosurg 99:1039-1046, 2003

123. Yong VW, Prospects for Neuroprotection in multiple sclerosis, Frontiers Biosci 9:864-872, 2004 124. Tsutsui S, Schnermann J, Noorbakhsh F, Yong VW, Warren K, Power C, A1 Adenosine

receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of

Yong 16

multiple sclerosis, J Neurosci 24:1521-1529, 2004 125. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P,

Antel JP, Mitchell JR, Minocycline Reduces Gadolinium-enhancing MRI Lesions in Multiple Sclerosis, Ann Neurol 55:756, 2004

126. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW, Pro-regenerative properties of

cytokine stimulated astrocytes, J Neurochem, in press 127. Zhou Y, Liu Q, Bell R, Muruve DA, Forsyth P, Robbins S, Yong VW, The chemokine GRO-α

(CXCL1) confers increased tumorigenicity to glioma cells, revised for Mol Cancer Res 128. Weaver A, Nuttall RK, Edwards DR, Shapiro SD, Yong VW, An elevated matrix metalloproteinase

in experimental autoimmune encephalomyelitis is protective by affecting Th1/Th2 polarization, revised for J Immunol

129. Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, Wallace JL, Deacon RM,

Hao C, Warren K and Power C. An endogenous retrovirus glycoprotein is toxic to oligodendrocytes in a mouse multiple sclerosis model, revised for Nature Neurosci

130. Wells JEA, Biernaskie J, Szymanska A, Yong VW, Corbett DR, Matrix metalloproteinase (MMP)-

12 expression following intracerebral hemorrhage has a negative impact on sensorimotor function in mice, revised for Eur J Neurosci

131. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW, Synergistic effect of the combination

of glatiramer acetate and minocycline in a model of MS, submitted 132. Ladiwala U, Zhou Y, Howlett C, Robbins SM, Yong VW, Inhibition of the α6β1 integrin receptor

on oligodendrocytes promotes signaling and cell death, submitted 133. Giuliani F, Zabad R, Yong VW, Multiple sclerosis and CIDP: two faces of the same coin? Lancet

Neurol, invited review, submitted 134. Giuliani F, Yong VW, Minocycline attenuates T cell activity to impair cytokine production in T

cell - microglia interaction, submitted

Book chapters

10. Yong VW, Sadikot AF, Baltuch GH, Inflammatory cytokines, astrocytes and the regeneration of the central nervous system, in: Clinical Neuroimmunology, JP Antel, G Birnbaum and HP Hartung (ed), Blackwell Science, Cambridge, pp. 271-280, 1998

11. Sadikot AF, Yong VW, Immunology of central nervous system grafts, in: Clinical

Neuroimmunology, JP Antel, G Birnbaum and HP Hartung (ed), Blackwell Science, Cambridge, pp 281-293, 1998

Yong 17

12. Yong VW, Antel JP, Culture of glial cells from human brain biopsies, in: Protocols for neural cell culture, 3rd Edition, A Richardson and S Fedoroff (ed), Humana Press, St. Louis, pp 129-138, 2001

13. Forsyth P, Lafleur M, Edwards D, Yong VW, Proteases and their inhibitors in gliomas, in:

Role of proteases in the pathophysiology of neurodegenerative diseases, Lajtha A, Banik NL (ed), Kluwer Academic/Plenum Publishers, NY, pp 241-268, 2001

14. Chabot S, Yong VW, Microglia in the CNS, in: Neuronal microenvironment, W Walz (ed),

Humana Press, Totowa, NJ, pp 379-399, 2002

15. Yong VW, Expression, function and interactions of chemokines in CNS trauma, in: Universes in delicate balance: chemokines and the nervous system, R Ransohoff (ed), Elsevier Science, 151-158, 2002

16. Yong VW, Ransohoff RM, Inflammatory cytokines in CNS trauma, in: Inflammation and

Stroke, G Feuerstein (ed), Birkhauser Verlag AG, Basel, pp 181-192, 2002 17. Yong VW, Immunopathogenesis of MS, In: Continuum on Multiple Sclerosis, a special series

published by the American Academy of Neurology, in press

18. Giuliani F, Zabad R, Yong VW, Neuroprotective effects of interferon-β in multiple sclerosis, in: Inflammatory disorders of the nervous system: Pathogenesis, immunology and clinical management, Ed: A. Minagar, JS Alexander, Humana Press, New Jersey, in press

I. OTHER SCHOLARLY CONTRIBUTIONS 1. Member, Medical Advisory Committee, Multiple Sclerosis Society of Canada, 1999 – present 2. Member, Senior Research Programs Advisory Committee, National Multiple Sclerosis Society

(USA), 2002 – present 3. Director, Canadian Institutes of Health Research, Interdisciplinary Health Research Team

Program on: Matrix metalloproteinases in multiple sclerosis: Environmental influence, biology, pathology and therapeutic strategies. There are 14 other investigators in this program (Jack Antel, Amit Bar-Or, Pierre Duquette, Dylan Edwards, Peter Forsyth, Charlie Hao, Paul Kubes, Luanne Metz, Ross Mitchell, Trevor Owens, Scott Patten, Jim Peeling, Christopher Power and Steven Robbins). The award is a total of $989,650 per annum for the whole team, from 2001 – 2006. $119,863 is awarded for equipment in 2001

4. Editorial board member of the journals GLIA and Journal of Neuroscience Research, 2001 –

present 5. Member, Task Force on the Future of the American Society for Neurochemistry, 2001 – present 6. Member, Neuroscience B Grants Review Panel, Canadian Institutes of Health Research, 2003 –

present

Yong 18 7. Member by invitation, Pathology and Morphology Grants Review Panel, Canadian Institutes of

Health Research, 2003 8. Convenor, Symposium on MMPs in the nervous system: Functions in Physiology, Pathology and

Recovery, at the 34th Annual Meeting of the Society for Neurochemistry, NewPort, CA, May 3-8, 2003

9. Chair, Biomedical Grants Review Committee, Multiple Sclerosis Society of Canada, 1999 – 2002 10. Member, Grants Review Panel, Multiple Sclerosis Society of Canada, 1995 – 2002 11. Member, Fellowship Committee, Alberta Heritage Foundation for Medical Research, 1999 –

2002 12. Member, Fellowship Committee, Medical Research Council of Canada, 1999 – 2002 13. Convenor, Symposium on MMPs at the International Society for Neuroimmunology Congress,

Edinburgh, Sept 4-7, 2001 14. Chair, Organising committee on behalf of the Multiple Sclerosis Society of Canada. Conference

on: Conquering multiple sclerosis: Research in Canada in the new millineum, Banff, Dec 2 – 5, 2000

15. Member, Grants Review Panel, Alberta Cancer Foundation, 1998 – 2000 16. Chair, Organising Committee, International Conference on Metalloproteinases and their Inhibitors

in the Nervous System: Physiology and Disease, Banff, Feb 27 - March 3, 1999 17. Member, Grants Review Panel, Medical Research Council of Canada, Pathology and Morphology

Committee, 1995 – 1998 18. Chairperson of The CNS as an immune organ symposium, at the 5th International Congress of the

International Society of Neuroimmunology, Montreal, 1998 19. Co-organizer (with Dr. Martin Rumsby, UK), on Protein kinase C in glia workshop, 1 of 15

workshops at the Joint Meeting of the International Society of Neurochemistry and the American Society of Neurochemistry, Boston, 1997

20. Organising Committee, 7th Canadian Neuro-oncology meeting, Montreal, 1996 J. CURRENT/PAST ADMINISTRATIVE RESPONSIBILITIES AT THE UNIVERSITY OF CALGARY

1. Chair, Organising Committee, Calgary Brain Institute Research Day, March 12, 2004

Yong 19

2. Chair, Organizing committee, Calgary Neuroscience Research Day, Dec 1997, 1998, 1999, 2000 and 2001

3. Chair, Organizing committee, Department of Clinical Neurosciences Research Day, April 2000,

2001, 2002 and 2003

4. Co-director, MS Program of the Calgary Brain Institute, 2003 - present

5. Committee member, Neuroscience Research Group Executive Board, 1998 – 2002

6. Chair, Research Committee, Department of Clinical Neurosciences, 1999 – 2003

7. Committee member, Basic Science Accredition Task Force for 2000, Faculty of Medicine

8. Co-director, Partners in Health Brain Tumor Research Pipelines

9. Committee member, Search Committtee for the Brenda Strafford Chair in Alzheimer Research, 1999 - 2001

10. Committee member, Alberta Heritage Lectureship Award, Faculty of Medicine, 2003 - present

K. SERVICE TO THE COMMUNITY 1. Organiser, Science Day for 100 primary school students, held at the Medical School, Faculty of

Medicine, April 2, 1998 2. Organiser, Science Day for 100 primary school students, to be held at the Medical School,

Faculty of Medicine, April, 2000 3. Talk to the community of Westlock, Alberta, on: Current Trends in MS Research, November 24,

1998 4. Keynote speaker, Multiple Sclerosis Society, Calgary Chapter Annual General Meeting, Oct 30,

1999 5. Board Member, Calgary Chapter, Multiple Sclerosis Society, 1999 – present 6. Organiser, Science Day for 135 primary school students, held at the Medical School, Faculty of

Medicine, April 18, 2000 7. Keynote speaker, Multiple Sclerosis Society, Calgary Chapter Annual General Meeting, Nov 3,

2001

Yong 20

L. TRAINEES IN THE LABORATORY Current Trainees 1. Peter Larsen (M.Sc. Odense University), from May 2000, Ph.D. candidate. Source of support:

Danish Academy of Science, Multiple Sclerosis Society of Canada and Alberta Heritage Foundation for Medical Research

2. Jennifer Dowden (PhD, Memorial University), from Feb 2000, Postdoctoral fellow. Source of

support: Alberta Heritage Foundation for Medical Research 3. Fabrizio Giuliani (Neurologist, University of Bari, Italy), from Feb 2001, Postdoctoral fellow.

Source of support: Alberta Heritage Foundation for Medical Research 4. Tiffany Rice (B.Sc. University of Calgary), from Sept 2001, Ph.D. candidate. Source of support:

National Science and Engineering Research Corporation and Alberta Heritage Foundation for Medical Research

5. Jing Zhang (PhD, Sun Yat-Sen University of Medical Sciences, Guangzhou, China), from Nov

2002, Postdoctoral fellow. Source of support: Alberta Cancer Foundation 6. Rana Zabad (Neurologist, Wayne State University), from September 2002, Clinical Fellow,

spends 2 days/week in the lab. Source of support: Multiple Sclerosis Society of Canada 7. Susobhan Sarkar (PhD, University of Calcutta), from May 2003, Postdoctoral fellow. 8. Tiona Toduruk (PhD, University of Calgary), from May 2003, Postdoctoral fellow. Source of

support: Alberta Heritage Foundation for Medical Research and Neuroscience Foundation Canada.

9. Jennifer Ah-Sue (BSc, Queen’s University), from July 2003, M.Sc. candidate 10. Angelika Da Silva (BSc, Carlton University), from Sept 2003, Ph.D. candidate 11. Rowena Cua (BSc, University of British Columbia), from Sept 2003, M.Sc. candidate 12. Hui Li, (MD China), Neurosurgery resident on basic science rotation in my lab. Current Technicians: 1. Fiona P. Yong 2. Tammy Wilson 3. Yan Fan

Yong 21 Administrative Assistant: Tanna Giroux Past Trainees: 1. William Couldwell, 1989 - 1991, Ph.D. degree, obtained 1991. Source of support: MRC

Centennial Fellowship. Current Position: Chairman, Department of Neurosurgery, University of Utah

2. Robert Moumdjian, 1989 - 1991, M.Sc. degree, obtained 1991. Source of support: Jeanne

Timmins Fellowship. Current Position: Associate Professor, University of Montreal 3. Jason CB Cheung, 1989, Summer Student Source of support: McGill Medical Student Research

Program. Current Position: Ophthalmologist 4. Joon H. Uhm, 1989, Winter Student; also 1990, Summer Student. Also: Neurology Resident on 6

months Basic Science Rotation, 1994 – 1995. Current Position: Staff, Mayo Clinic, Rochester 5. Amit Bar-Or, 1991, Winter Student . Source of support: McGill Medical Student Research

Program. Current Position: Assistant Professor, McGill University 6. Garnet Fraser, 1991, Summer Student, Source of support: FRSQ. Last known Position: Final Year

Medical Student, Queen's University 7. Paul Noble, 1990 - 1992, Neurology Resident on Basic Science Rotation. Current Position:

Neurologist in private practice, Montreal 8. Erin Wright, 1991, Summer Student; also 1991, Winter Student. Source of support: McGill

Medical Student Research Program. Last known Position: ENT Fellowship, University of Pennsylvania

9. Trevor Tejada-Berges, 1991 - 1993, M. Sc. Degree. Source of support: Supervisor's grant. Last

known position: Final Year Resident in Obstetrics and Gynecology, McGill University 10. Jolanda Turley, 1992 and 1993, Summer Student. Source of support for 1992: Supervisor's MRC

Grant. Source of support for 1993: Challenge 1993, Last known Position: Final Year Medical Student, McGill University

11. Anthony Brade, 1993, Summer Student. Source of support: McGill Medical Student Research

Program. Last known position: Finished MD degree, 1995. 12. Gordon Baltuch, 1991 - 1994, Ph.D. degree. Source of support: MRC Fellowship. Current

Position: Assistant Professor, University of Pennsylvania 13. Vijayabalan Balasingam, 1991 - 1995, M.D./Ph.D. degree. Source of support: National Centre of

Excellence. Current Position: Neurosurgery Fellow, MD Anderson Cancer Centre, Texas

Yong 22 14. Olaf Stuve, from 1995 - 1996, Postdoctoral Fellow. Source of support: Deutsche

Forschungsgemeinschaft (German equivalent of MRC). Current Position: Neurology Fellow, University of California at San Franscisco

15. Alexis Armour, May - August, 1995, Summer student. Source of support: University of Toronto

Medical Student Bursary Program and MRC. Current Position: Plastic Surgery Resident, University of Toronto

16. Tarek Boutros, 1993 - 1997, M.Sc. degree. Source of support: Berlex Laboratories. Current

Position: Research Technician, McGill University 17. Nora Dooley, 1991 - 1998, Ph.D. degree. Source of support: FCAR and NCE. Current Position:

Housewife 18. Jack Vecil, 1998, Neurosurgery Resident on 6 months Basic Science Rotation. Current

position: Final Year Neurosurgery residency 19. Luke Oh, 1994 - 1999, Ph.D. degree. Source of support: Multiple Sclerosis Society of Canada.

Current position: Postdoctoral fellow, University of Connecticut 20. Sophie Chabot (B.Sc. McGill University), 1995 – 2000, Ph.D. degree. Source of support:

Multiple Sclerosis Society of Canada. Current position: Postdoctoral fellow, McGill University 21. Veronika Brundula (B.Sc. Simon Bolivar University, Venezuela), from 1998 - 2000, M.Sc.

degree. Current position: Medical School, University of Montreal 22. Shannon Corley (B.Sc. University of Victoria), from 1998 - 2000, M.Sc. degree. Current

position: Research Technician 23. Uma Ladiwala (M.D. India), from 1999 - 2000, Postdoctoral fellow. Current position: Research

Scientist, India 24. Arnaud Besson (M.Sc Grenoble University, France), 1997 - 2001, Ph.D. degree. Source of

support: National Cancer Instutute of Canada and AHFMR. Current position: Postdoctoral fellow, Fred Hutchinson Cancer Center, Seattle, Washington.

25. Leonie Moorhouse-Herx (B.Sc. McGill University), from September 1997, MD/Ph.D. candidate.

Source of support: MRC MD/PhD Studentship and AHFMR. PhD obtained in 2001. 26. Le Duc (B.Sc. University of Waterloo), 1999 –2001, M.Sc. degree. Source of support: NSERC

studentship and AHFMR. Current position: Medical School, University of Toronto 27. Charlotte Verhaege, Medical Student from the University of Alberta, for 3 months summer

studentship, 2001. Current position: Medical School, University of Alberta 28. Jennifer Takahashi, Neurology Resident at the University of Calgary, for 6 months laboratory

basic research program, from July 2001

Yong 23 29. Yan Zhou (Ph.D. Justus Liebig University, Giessen), from 2000 - 2002, Postdoctoral fellow.

Source of support: AHFMR. Current position: Scientist, Vaccine Centre, University of Saskatoon 30. Andrew Weaver (B.Sc. University of Victoria), 2001 – 2003, M.Sc. degree. Current position:

Medical School, University of Calgary The following trainees achieved Institutional or International honors for presentations of their work:

Institutional: 1. Cheung JCB, McGill Ciba-Geigy and UpJohn Awards, 1989, for: Role of protein kinase C

in process extension by rat oligodendrocytes 2. Moumdjian RM, Killam Award of Fellow's day, Department of Neurology and

Neurosurgery, McGill, 1990, for: Modulation of reactive gliosis in vivo 3. Uhm JH, Joint winner of McGill Ciba-Geigy Award, 1990, for: Protein kinase C activity

in human malignant gliomas 4. Bar-Or, A Joint winner of McGill Ciba-Geigy Award, 1990, for: Biological characteristics

of human microglia in tissue culture

5. Couldwell WT, Dean's Honor List and Grade of Excellent, 1991, for presentation of Ph.D. thesis, entitled: Autocrine and paracrine growth regulation in human malignant gliomas

6. Wright E, McGill FRSQ Prize of Excellence, 1991, for: Reactive gliosis in the neonatal

mouse brain and its regulation by cytokines 7. Baltuch GH, Killam Award of Fellow's day, Department of Neurology and Neurosurgery,

McGill, 1993, for: Regulation of glioma growth by PKC isozymes 8. Baltuch GH, Janssen Award, Department of Neurology and Neurosurgery, McGill, 1993,

for: Regulation of glioma growth by PKC isozymes 9. Uhm JH, Killam Award of Fellow's day, Department of Neurology and Neurosurgery,

McGill, 1995, for: Glioma invasion requires a 72 kDa metalloprotease that is regulated by protein kinase C

10. Uhm JH, CSCI/MRC Resident Research Award for McGill University, 1996

11. Chabot S, Best oral presentation by a graduate student, Department of Clinical

Neurosciences Research Day, University of Calgary, 1998

12. Besson A, Graduate Faculty Council Scholarship, University of Calgary, 1998 13. Herx LM, Best oral presentation by a graduate student, Department of Clinical

Neurosciences Research Day, University of Calgary, 1999

Yong 24

14. Veccil G, Best oral presentation by a resident, Department of Clinical Neurosciences Research Day, University of Calgary, 1999

15. Herx LM, University of Calgary Killam scholarship, 1999

16. Corley S, Best oral presentation by a graduate student, Department of Clinical

Neurosciences Research Day, University of Calgary, 2000

17. Jennifer Takahashi, Best oral presentation by a resident, Department of Clinical Neurosciences Research Day, University of Calgary, 2002

18. Jennifer Wells, Best oral presentation by a basic science fellow, Department of Clinical

Neurosciences Research Day, University of Calgary, 2002

19. Yan Zhou, Best poster presentation by a basic science fellow, Department of Clinical Neurosciences Research Day, University of Calgary, 2002

Provincial/National/International: 1. Cheung JCB, Saul Korey Award of the American Academy of Neurology, 1990, for: Role

of protein kinase C in process extension by rat oligodendrocytes 2. Couldwell WT, Preuss Award, American Association of Neurological Surgeons, 1990,

for: Inhibition of growth of established human glioma cell lines by modulators of the protein kinase C second messenger system

3. Couldwell WT, Preuss Award, American Association of Neurological Surgeons, 1991,

for: Enhanced protein kinase C activity in human malignant gliomas determines their high proliferative rate

4. Wright E, Saul Korey Award of the American Academy of Neurology, 1992, for: Reactive

gliosis in the neonatal mouse brain and its regulation by cytokines 5. Baltuch GH, KG McKenzie Prize for Basic Science Research of the Canadian

Neurological Society, at Canadian Congress of Neurological Sciences, 1994, for: Protein kinase C isoform α overexpression in C6 glioma cells and its role in cell proliferation

6. Uhm JH, Andre Barbeau Prize of the Canadian Neurological Society, 1995, for: Glioma

invasion requires a 72 kDa metalloprotease that is regulated by protein kinase C 7. Oh LYS, Best poster prize, 4th International Altschul Symposium on Cell Biology and

Pathology of Myelin, Saskatoon, 1996 8. Uhm JH, 1997 Founders Award of the American Academy of Neurology, for: Migratory

behavior of lymphocytes isolated from MS patients undergoing treatment with interferon-β 1b.

Yong 25

9. Uhm, JH, MRC Clinician-Scientist Award, 1997 10. Moorhouse-Herx L, Canada Neuroscience Foundation, Special recognition studentship

award, 1999

11. Duc Le, Best Presentation at the Annual Alberta Cancer Board meeting, Nov 2000

12. Duc Le, Best Poster Prize, American Brain Tumor Association, Chicago, Nov 2000

13. Besson A, Selected for presentation at the Gordon Conference on Integrins, Feb 2001

14. Dowden J, Canada Neuroscience Foundation, Special recognition Postdoctoral fellowship award, Jan 2001

15. Larsen P, Travel Award, Gordon Conference on metalloproteinases, Italy, May 2001

16. Jennifer Takahashi, Brainstar Award, Canadian Institutes of Health Research, April 2004

2000: External reviewer of PhD theses of: • Gwen Schwartz, University of Toronto (supervisor: Michael Fehlings) • Shalina Ousman, McGill University (supervisor: Sam David) • Elise Tran, McGill University (supervisor: Trevor Owens) 2001: External reviewer of PhD theses of: • LiWei Hua, Albert Einstein College of Medicine (supervisor: Sunhee Li) • Omari Kakuri, University of British Columbia (supervior: Katerina Dorovini-Zis) 2002: External reviewer of PhD theses of: • Armani Kochid, McGill University (supervisor: Guillermina Almazan) 2004: External reviewer of PhD theses of: • Dai Ruping, University of Singapore (supervisor: Samuel Tay Sam Wah) Member of thesis advisory committee of (current listing, and not including the students that I supervise directly in my lab): • Chris Gregg (PhD candidate), supevisor: Sam Weiss • Jennifer Pelley (PhD candidate), supervisor: Chris Brown • Jennifer Hocking (PhD candidate), supervisor: Sarah McFarlane • Daniel Warren (MSc candidate), supervisor: Alastair Buchan • Isabelle Latour (PhD candidate), supervisor: Brian MacVicar/Gerald Zamponi • Cindi Sondergaard (MSc candidate), supervisor: Peter Forsyth

Yong 26 • Darrin Fogg (PhD candidate), supervisor: David Waisman • LiBo Zhang (MSc candidate), supervisor: David Waisman • Lin Ma (PhD candidate), supervisor: Carol Schuurmans and Sarah McFarlane • Tina Dubois (MSc candidate), supervisor: Sam Weiss • Angela McDermid (PhD candidate), supervisor: Peter Forsyth • Alex Klimowicz (PhD candidate), supervisor: Stephen Robbins • Alan Box (MSc candidate), supervisor: Stephen Robbins • Yun Yan Zhang (PhD candidate), supervisor: Ross Mitchell • Joseph Antony (PhD candidate), supervisor: Christopher Power • Jeff Dai (MSc candidate), supevisor: Chris Brown • Sukbadeep Chakrabarti (PhD candidate), supervisor: Kamala Patel